Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Other Non Operating Income for 4 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 50.91% year-over-year to $3.5 million, compared with a TTM value of $11.6 million through Dec 2025, up 23.07%, and an annual FY2025 reading of $11.6 million, up 23.07% over the prior year.
  • Other Non Operating Income was $3.5 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $3.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.5 million in Q4 2025 and bottomed at $34000.0 in Q1 2022.
  • Average Other Non Operating Income over 4 years is $1.9 million, with a median of $2.3 million recorded in 2024.
  • The sharpest move saw Other Non Operating Income surged 5288.24% in 2023, then decreased 2.07% in 2024.
  • Year by year, Other Non Operating Income stood at $794000.0 in 2022, then skyrocketed by 198.36% to $2.4 million in 2023, then decreased by 2.07% to $2.3 million in 2024, then soared by 50.91% to $3.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for KNSA at $3.5 million in Q4 2025, $3.1 million in Q3 2025, and $2.7 million in Q2 2025.